A month has gone by since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 21.4% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Beam Therapeutics (BEAM) said that the U.S. FDA cleared the investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic condition ...

U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE ...